Status:
UNKNOWN
High Dose Hyperoncotic Serum Albumin for the Treatment of the Acute Phase of Severe Head Injury
Lead Sponsor:
University Hospital, Angers
Conditions:
Severe Head Injury
Eligibility:
All Genders
18-55 years
Phase:
PHASE2
PHASE3
Brief Summary
Experimentally high dose of hyperoncotic human serum albumin improve neurological recovery after head injury reduce cerebral edema and normalize apparent diffusion coefficient of water after ischemia ...
Eligibility Criteria
Inclusion
- severe head injury (GCS \< 9) Next of kin informed consent
Exclusion
- Cranio cerebral wound Pregnancy Hypoxemia (PaO2/FiO2\< 300 mmHg) Blood loss \> 1/2 blood mass Renal or cardiac failure,uncontrolled hypertension Head injury dating from more than 24 hours at the time of inclusion
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00152685
Last Update
December 1 2005
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Surgical intensive care. CHU
Angers, Cedex 9, France, 49993
2
Neurosurgical intensive care. CHU Le Kremlin Bicêtre
Le Kremlin-Bicêtre, France, 94275
3
Neurosurgical intensive care. CHU de Nancy
Nancy, France, 54035